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PCardiac Imaging
Prognostic Value of 64-Slice
Cardiac Computed Tomography
Severity of Coronary Artery Disease, Coronary Atherosclerosis,
and Left Ventricular Ejection Fraction
Benjamin J. W. Chow, MD,*‡ George A. Wells, PHD,† Li Chen, MSC,† Yeung Yam, BSC,*
Paul Galiwango, MD,* Arun Abraham, MBBS,* Tej Sheth, MD,§ Carole Dennie, MD,‡
Rob S. Beanlands, MD,*‡ Terrence D. Ruddy, MD*‡
Ottawa and Hamilton, Ontario, Canada
Objectives We sought to determine the prognostic and incremental value of coronary artery disease (CAD) severity, coro-
nary atherosclerosis, and left ventricular ejection fraction (LVEF) measured with cardiac computed tomography
angiography (CTA).
Background CTA is an emerging tool used for the detection of obstructive CAD. However, there are limited data supporting
the prognostic value of 64-slice CTA and its ability to predict all-cause mortality and major adverse cardiac
events such as cardiac death and nonfatal myocardial infarction.
Methods Consecutive patients (without history of revascularization, heart transplantation, and congenital heart disease)
were prospectively enrolled. Each CTA was evaluated for CAD severity, total plaque score, and LVEF. Patients
were followed, and all events were confirmed with death certificates or hospital or physician records and re-
viewed by a clinical events committee.
Results Between February 2006 and February 2008, 2,076 consecutive patients were prospectively enrolled and fol-
lowed for a mean of 16  8 months. At follow-up, a total of 31 (1.5%) patients had cardiac death or nonfatal
myocardial infarction and 47 (2.3%) had all-cause mortality or nonfatal myocardial infarction. Multivariate analy-
sis showed that CAD severity (hazard ratio [HR]: 3.02; 95% confidence interval [CI]: 1.89 to 4.83) was a predic-
tor of major adverse cardiac events and that LVEF (HR: 1.47; 95% CI: 1.17 to 1.86) had incremental value over
CAD severity. Total plaque score had incremental value over CAD severity and LVEF for all-cause mortality and
nonfatal myocardial infarction (HR: 1.17; 95% CI: 1.06 to 1.29).
Conclusions Using CTA, CAD severity, LVEF, and total plaque score seems to have prognostic and incremental value over rou-
tine clinical predictors. Cardiac CTA seems to be a promising noninvasive modality with prognostic
value. (J Am Coll Cardiol 2010;55:1017–28) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.10.039h
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apidly emerging noninvasive diagnostic tool for the detec-
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ccepted October 12, 2009.ave demonstrated that CTA has good operating charac-
eristics for the diagnosis of CAD and may reduce referrals
or invasive coronary angiography (1–5).
CTA seems to be a promising modality, but there are
imited data supporting the prognostic value of 64-slice CTA.
arly studies demonstrated that CTA is a predictor of all-cause
ortality (6,7), and smaller studies demonstrated that CTA is
n independent predictor of cardiac events (8–10). To further
See page 1029
upport the clinical acceptance of CTA, larger cohort studies
re needed to understand the prognostic value of 64-slice CTA
n major adverse cardiac events (MACE) such as cardiac death
nd nonfatal myocardial infarction (MI).
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have shown that severity of
CAD, left ventricular ejection
fraction (LVEF), and coronary
atherosclerosis all have prognos-
tic value and predict MACE
(11–13). However CTA is a
unique noninvasive modality
with the ability to obtain all 3
measures (CAD severity, LVEF,
and coronary atherosclerosis)
with a single image acquisition.
The objective of this large pro-
spective cohort study is to under-
stand the potential prognostic and
incremental value of 64-slice CTA
using measures of CAD severity,
coronary atherosclerosis, plaque
characteristics, and LVEF.
Methods
Between February 2006 and
February 2008, consecutive pa-
ients undergoing CTA were prospectively enrolled in a
ardiac computed tomography (CT) registry (5) and were
ollowed for all-cause mortality and MACE (cardiac death
nd nonfatal MI). Patients with a history of coronary
evascularization, heart transplantation, and congenital
eart disease were excluded. The study was approved by the
niversity of Ottawa Heart Institute Human Research
thics Board, and all patients provided written informed
onsent.
linical predictors. At the time of CTA, a medical history
nd laboratory test results were recorded for all patients.
re-test probability for obstructive CAD was calculated for
ndividual patients using age, sex, and symptoms (14–16).
ased on the National Cholesterol Education Program/
dult Treatment Panel III Guidelines, cardiac risk factors
smoking, hypertension [blood pressure 140/90 mm Hg
n antihypertensive medication], family history of prema-
ure CAD [first-degree family member (men younger than
5 years of age and women younger than 65 years of age)
ith a history of MI or revascularization], dyslipidemia
based on a fasting lipid profile or treatment for hyperlip-
demia], and diabetes) were used to estimate each patient’s
isk of a future cardiac event (17).
TA. Before image acquisition, metoprolol or diltiazem
oral and/or intravenous) was administered, targeting a
eart rate of 65 beats/min. Patients without contraindi-
ations received nitroglycerin (0.8 mg) sublingually (18,19).
A biphasic timing bolus (15 to 25 ml of contrast; 40 ml
f saline solution; 5 to 9 ml/s) was used to measure transit
ime (interval between intravenous contrast [Visipaque 320
r Omnipaque 350, GE Healthcare, Milwaukee, Wiscon-
Abbreviations
and Acronyms
CAD  coronary artery
disease
CI  confidence interval
CT  computed
tomography
CTA  cardiac computed
tomography angiography
ECG  electrocardiogram
HR  hazard ratio
LV  left ventricular
LVEF  left ventricular
ejection fraction
MACE  major adverse
cardiac events
MI  myocardial infarction
NRI  net reclassification
improvement
TPS  total plaque score
VD  vessel diseasein] infusion and peak aorta opacification) (5). sCTA image acquisition, using a triphasic intravenous
ontrast administration protocol (100% contrast, 40%/60%
ontrast/saline solution [50 ml], and saline solution [40
l]), was initiated 2 seconds after the calculated transit
ime. The volume of the second phase (contrast/saline
olution) was increased if assessment of right-sided struc-
ures was indicated. The volume and rate (5 to 9 ml/s) of
ontrast were individualized according to scan time and
atient body habitus (5,18). Flow rates of 8 ml/s were
eserved for patients with a very high body mass index
nd/or significant chest wall attenuation.
Retrospective electrocardiogram (ECG)-gated datasets
ere acquired with the GE Volume CT (GE Healthcare)
ith 64 0.625-mm slice collimation and a gantry rotation
f 350 ms (mA 400 to 800, kV 120) using ECG-gated
-ray tube modulation (200 to 275 mA) with the peak
illiamperes between 70% and 80% phases. Pitch (0.16 to
.24) was individualized according to heart rate. The CTA
atasets were reconstructed, at the 70%, 75%, and 80%
hases using a slice thickness of 0.625 mm with an incre-
ent of 0.4 mm (5). If significant cardiac motion was
resent, additional phases were reconstructed. An additional
0 phases (5% to 95%) were reconstructed with 1.25-mm
lice collimation with an increment of 0.625 mm and were
sed to measure left ventricular (LV) volumes.
TA image analysis. ECG-gated CT images were post-
rocessed using the GE Advantage Volume Share Work-
tation (GE Healthcare) and interpreted by expert observers
2 years of experience) blinded to all clinical data. To
mulate clinical practice, the blinded interpretation of the
bserver who would eventually be clinically responsible for
he interpretation was used for analysis. Coronary artery
umen and plaque were assessed using axial images, oblique
ultiplanar reformations, and window levels and widths
ptimized for each study to enable the identification of
oronary atherosclerotic plaque (20).
A 17-segment model of the coronary arteries and 4-point
rading score (normal, mild [50%], moderate [50% to
9%], severe [70%]) was used for the evaluation of
oronary diameter stenosis (21). In segments that were
nevaluable, forced reading was performed and readers
rovided their best educated guess. Patients were catego-
ized into 3 broad categories (normal, nonobstructive CAD,
bstructive CAD). Patients with obstructive CAD were
urther categorized as having high-risk CAD (defined as
aving a left main stenosis [50%], 3-vessel disease [VD]
70%], or 2-VD [70%] involving the proximal left
nterior descending artery) or non–high-risk CAD (CAD
odel 1) (22,23). In addition, patients with obstructive
AD (50% diameter stenosis) were categorized as 1-, 2-,
r 3-VD (CAD model 2) (7).
The same 17-segment model of the coronary arteries
2,21) was used for the evaluation and visual semiquantifi-
ation of coronary artery calcific, noncalcific, and mixed
laque. The total plaque score (TPS) was determined by
umming the number of assessable coronary segments with
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March 9, 2010:1017–28 Prognosis of Cardiac CTalcific, noncalcific, or mixed plaque (maximum score 
7). The same method was used to sum segments according
o plaque composition (isolated calcific, isolated noncalcific
laque, and mixed plaque).
Using a semiautomated volumetric algorithm (Advantage
orkstation, Ejection Fraction, GE Healthcare), LV vol-
mes were measured at end diastole and end systole, and the
VEF was calculated (24).
atient follow-up. Patient follow-up was performed (6-
onth intervals) by telephone interview by trained research
taff blinded to all clinical data. All events were confirmed
ith death records, hospital records, or correspondence with
reating physicians. All events were reviewed by a blinded
linical events committee composed of 2 clinical cardiolo-
ists and a nurse.
utcome measures. The primary outcome measure was a
omposite of all MACE (cardiac death and nonfatal MI).
ll deaths were reviewed and classified as cardiac or non-
ardiac. Nonfatal MI was defined as myocardial ischemia
esulting in abnormal cardiac biomarkers (99th percentile of
he upper limits of normal) (25). A secondary composite
utcome (all-cause mortality and nonfatal MI) and all-cause
ortality were also assessed. Revascularized patients were not
xcluded from analysis.
tatistical analysis. Statistical analyses were performed
G.W. and L.C.) using SAS (version 9.1.3, SAS Institute
nc., Cary, North Carolina), and statistical significance was
efined as p  0.05. Continuous variables are presented as
eans and SDs, and categorical variables are presented as
requencies with percentages. To compare patient charac-
eristics and CTA imaging parameters, Wilcoxon rank sum
est was used to compare continuous variables, and the
isher exact test was used for categorical variables.
The prognostic value of CAD severity for unadjusted and
djusted outcomes and cardiac events was assessed for the
tudy population. All unadjusted comparisons of cardiac
vents were performed with survival analysis log-rank tests.
nnual event rates were calculated by dividing the Kaplan-
eier event rates by mean number of years of follow-up.
For the risk-adjusted analysis, Cox proportional hazard
odels were used to assess the independent prognostic value
f CAD severity (controlling for baseline patient character-
stics) and create adjusted survival curves. The Cox models
ith and without CAD severity, LVEF, and TPS measures
ere compared to determine their incremental values. The
ncremental prognostic values of these measures were de-
ned by a statistically significant increase in the global
hi-square value of the models with CAD severity, LVEF,
nd TPS. The incremental values of plaque characteristics
ver CAD severity and LVEF were also evaluated using the
ox models. Receiver-operator characteristic curves were
onstructed for clinical predictors and for a model of clinical
redictors and CAD severity. Area under the curves was
ompared to evaluate each model’s ability to predict MACE
26). The improvement of reclassification using the models
CAD severity, LVEF, and TPS) was also assessed by ralculating the net reclassification improvement (NRI) (27)
or 10-year categories of risk (10%, 10% to 20%, 20%
isk) (17).
esults
ver an enrollment period of 25 months, 2,609 consec-
tive patients underwent CTA with a total of 2,584
99.0%) patients prospectively enrolled in the University
f Ottawa Heart Institute Cardiac CT Registry. Of these,
12 patients with a history of coronary revascularization,
eart transplantation, and congenital heart disease were
xcluded. The remaining 2,172 patients (mean age 57.6
11.8 years, 52.6% men; mean pre-test probability for
bstructive CAD 33.4  34.4%) met the inclusion
riteria for this study. Primary indications for CTA were
hest pain (58.1%), and dyspnea (16.0%) (Table 1). Of
symptomatic patients, 241 (11.1%) had multiple cardiac
isk factors and CT was requested to rule out CAD, 139
6.4%) had an equivocal or abnormal stress test, and 84
3.9%) had CTA performed before noncoronary cardiac
urgery. Follow-up was obtained for 2,076 (95.6%) pa-
ients, with only 96 patients lost to follow-up. Compared
ith patients with follow-up, patients lost to follow-up
ere younger, had less hypertension, but were more likely
o have a family history of premature CAD (Table 1).
tatistically significant differences in imaging parameters
ere detected but were unlikely clinically significant
Table 2).
ardiac events. At follow-up, 31 patients had 34 MACE
ith 11 cardiac deaths and 23 nonfatal MIs (Table 3).
ll-cause mortality was observed in 27 patients, with 41%
ttributed to cardiac causes. Causes of the 16 noncardiac
eaths were malignancy (6 deaths), vascular event (3
eaths), sepsis (2 deaths), post-operative noncardiac com-
lication (2 deaths), and other (3 deaths). A total of 243
atients underwent revascularization (157 percutaneous cor-
nary interventions and 86 bypass surgeries).
nivariate analysis. Clinical parameters (age, smoking
istory, National Cholesterol Education Program/Adult
reatment Panel III risk, pre-test likelihood of CAD) and
T parameters (severity of CAD, TPS, LVEF) were all
ignificant predictors of MACE and all-cause mortality and
onfatal MI (Table 4).
AD severity and MACE. Patients without visible coro-
ary atherosclerosis had excellent prognoses, with only 1
atient dying of a nonischemic cardiac cause (metastatic
ardiac angiosarcoma). MACE were observed in 7 (0.8%) of
he 866 patients with nonobstructive CAD (Table 3).
Using a patient-based analysis, MACE occurred in 23
3.7%) of 619 patients with obstructive CAD (coronary
iameter stenoses50%). Using CAD model 1, 4 (4.1%) of
he 97 patients with high-risk CAD experienced MACE
ompared with 19 (3.6%) of 522 patients with non–high-
isk CAD. Using CAD model 2, MACE were observed in
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Prognosis of Cardiac CT March 9, 2010:1017–28.2%, 0.8%, 1.6%, 5.3%, and 7.0% of patients with no
AD, nonobstructive CAD, and 1-, 2-, and 3-VD,
espectively.
ox models of risk-adjusted outcomes. Clinical predic-
ors were identified and used to determine the incremental
alue of CTA measures (Table 4). A risk-adjusted model of
AD severity (model 1) was tested, and CAD severity
model 1) remained an independent predictor of MACE
fter adjusting for clinical characteristics (Table 5). Patients
ith high risk and non–high-risk obstructive CAD had
djusted hazard ratios (HRs) of 7.08 (95% confidence
nterval [CI]: 2.02 to 24.79) and 4.14 (95% CI: 1.70 to
0.05) (p  0.002).
A receiver-operator characteristic curve was created for
linical predictors versus clinical predictors plus CAD se-
erity (Fig. 1). The area under the curve for clinical
redictors plus CAD severity (model 1) (HR: 0.81; 95% CI:
.74 to 0.87) was significantly higher than those of the
linical predictors (HR: 0.72; 95% CI: 0.63 to 0.82; p 
.010) (Fig. 1) and was confirmed with reclassification
alibration (NRI: 22.4%, p  0.011).
ncremental prognostic value of CAD severity and
VEF. The incremental value of CAD severity and
Patient Characteristics: All Patients and PatienTable 1 Patient Characteristics: All Patient
All Patients
(n  2,172)
Mean follow-up (months) —
Age (yrs) 57.6 11.8
Men 1,142 (52.6%)
Body mass index (kg/m2) 29.1 6.3
Pre-test likelihood for CAD (%) 33.4 34.4
Cardiac risk factors
Smoker/ex-smoker 1,184 (54.5%)
Hypertension 1,112 (51.2%)
Dyslipidemia 1,151 (53.0%)
Treated with lipid-lowering agent 977 (45.0%)
Diabetes 309 (14.2%)
Family history of CAD 922 (42.4%)
Indications for study
Chest pain 1,262 (58.1%)
Nonanginal chest pain 607 (27.9%)
Atypical angina 317 (14.6%)
Typical angina 338 (15.6%)
Dyspnea 347 (16.0%)
History of chest pain (resolved) 6 (0.3%)
Palpitations 23 (1.1%)
Syncope 19 (0.9%)
Asymptomatic
Rule out CAD/cardiac risk factors 241 (11.1%)
Equivocal/abnormal stress test 139 (6.4%)
Pre-cardiac surgery 84 (3.9%)
LV dysfunction 13 (0.6%)
Other 38 (1.7%)
Values given are mean  SD or n (%). *Comparison of the patients w
CAD  coronary artery disease; LV  left ventricular.VEF was assessed for MACE. A statistically significant pncrease in global chi-square values confirmed that CAD
everity has the incremental value (43.81 vs. 24.97, p 
.001) over clinical predictors and that LVEF has incre-
ental value (54.48 vs. 43.81, p  0.001) over CAD
everity and clinical predictors (Table 5, Fig. 2). The
iscrimination of the CT model (clinical predictors,
AD severity, and LVEF) was significantly better than
hat of the clinical model (clinical predictors alone) (NRI:
9.5%, p  0.007). To ensure that model overfitting did
ot bias results, a sensitivity analysis was performed to
onfirm the incremental value of LVEF over CAD
everity and the remaining clinical predictor (pre-test
ikelihood of CAD) after excluding the clinical variable
ational Cholesterol Education Program.
nnual MACE. In our study population, the annualized
ate of MACE was 1.1%. The absence of obstructive CAD
onferred an excellent prognosis. Patients without visible
oronary atherosclerosis had a very low (0.1%) annual rate of
ACE, with slightly higher rates in patients with nonob-
tructive CAD (0.5%). Patients with obstructive CAD
coronary diameter stenoses 50%) had an annual MACE
ate of 2.7%. Using CAD model 1, patients with high-risk
AD had an annual rate of 5.8% compared with 3.3% in
th and Without Follow-UpPatients With and Without Follow-Up
w-Up Patients
n  2,076)
Patients Lost to Follow-Up
(n  96) p Value*
6.8 8.3 — —
8.0 11.7 50.6 11.8 0.001
087 (52.4%) 55 (57.3%) 0.200
9.1 6.3 28.7 5.9 0.685
3.4 34.3 32.1 35.7 0.193
129 (54.5%) 55 (57.3%) 0.326
076 (51.8%) 36 (37.5%) 0.004
103 (53.1%) 48 (50.0%) 0.309
40 (45.3%) 37 (38.5%) 0.209
00 (14.5%) 9 (9.4%) 0.103
69 (41.9%) 53 (55.2%) 0.007
204 (58.0%) 58 (60.4%) 0.463
77 (27.8%) 30 (31.3%) 0.485
02 (14.5%) 15 (15.6%) 0.767
25 (15.7%) 13 (13.5%) 0.667
31 (15.9%) 16 (16.7%) 0.887
5 (0.2%) 1 (1.0%) 0.641
20 (1.0%) 3 (3.1%) 0.121
19 (0.9%) 0 (0.0%) 0.715
31 (11.1%) 10 (10.4%) 0.890
33 (6.4%) 6 (6.3%) 0.893
82 (3.9%) 2 (2.1%) 0.501
13 (0.6%) 0 (0.0%) 0.946
38 (1.8%) 0 (0.0%) 0.359
without follow-up.ts Wis and
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March 9, 2010:1017–28 Prognosis of Cardiac CTodel 2, rates of MACE increased with the severity of
AD. Patients with 1-, 2-, and 3-VD had annual rates of
.4%, 4.3%, and 9.8%, respectively (Table 3).
CTA Imaging Parameters and ResultsTable 2 CTA I aging Parameters and Resul
All Patients
(n  2,172)
Fo
CTA imaging parameters
Imaging heart rate (beats/min) 57.2 7.5
Contrast infusion rate (ml/s) 6.2 0.9
Timing bolus (ml)
Contrast 19.2 5.0
Saline 40.0 0.0
Triphasic protocol (ml)
Phase I
Contrast 60.7 12.0
Phase II
Contrast 20.0 1.9
Saline 29.8 2.3
Total 49.9 3.5
Phase III
Saline 40.3 3.1
Total contrast volume (ml) 99.9 15.2
Effective dose (mSv)† 14.9 3.8
CTA results
Normal coronaries 623 (28.7%)
Nonobstructive CAD 908 (41.8%)
Obstructive CAD (50%) 641 (29.5%)
Obstructive CAD (70%) 446 (20.5%)
High-risk CAD 100 (4.6%)
Non–high-risk CAD 541 (24.9%)
LV ejection fraction (%) 64.1 10.5
LV end-diastolic volume (ml) 134.7 41.3
LV end-systolic volume (ml) 50.3 32.5
1 unassessable segment 217 (10.0%)
Values given are mean SD or n (%). *Comparison of the patients with
CTA  cardiac computed tomography angiography; other abbreviat
everity of CAD (Models 1 and 2) and Adverse Cardiac Events (N Table 3 Severity of CAD (Models 1 and 2) and Adverse Cardiac
n All Death Cardiac Death Non
CAD severity: model 1
No CAD 591 2 (0.3%) 1 (0.2%) 0
Nonobstructive CAD 866 8 (0.9%) 3 (0.4%) 5
Non–high-risk obstructive CAD 522 15 (2.9%) 6 (1.2%) 15
High-risk obstructive CAD 97 2 (2.1%) 1 (1.0%) 3
Log-rank p value 0.001 0.015 0
CAD severity: model 2
No CAD 591 2 (0.3%) 1 (0.2%) 0
Nonobstructive CAD (50%) 866 8 (0.9%) 3 (0.4%) 5
1-Vessel disease (50%) 321 9 (2.8%) 3 (0.9%) 4
2-Vessel disease (50%) 170 6 (3.5%) 3 (1.8%) 6
3-Vessel disease (50%) 128 2 (1.6%) 1 (0.8%) 8
Log-rank p value 0.001 0.012 0
oronary artery disease (CAD) model 1: patients were categorized into normal coronaries, nonobs
isease [70%] involving the proximal left anterior descending artery) or non–high-risk CAD. CAD m
isease (50% diameter stenosis).
MACE  major adverse cardiac events; MI  myocardial infarction.ncremental prognostic value of CAD severity, TPS, and
VEF. To prevent overfitting for the model, the incremen-
al value of CAD severity (model 1), LVEF, and TPS over
p Patients
2,076)
Patients Lost to Follow-Up
(n  96) p Value*
 7.5 57.9 7.5 0.223
 0.9 6.5 0.8 0.001
 5.0 20.8 4.6 0.001
 0.0 40.0 0.0 1.000
 12.1 62.9 8.3 0.001
 1.9 20.0 0.4 0.767
 2.4 29.9 0.6 0.606
 3.5 49.9 1.0 0.892
 3.2 40.2 1.4 0.878
 15.3 103.7 11.7 0.001
 3.8 15.1 2.9 0.266
(28.5%) 32 (33.3%) 0.179
(41.7%) 42 (43.8%) 0.384
(29.8%) 22 (22.9%) 0.089
(20.6%) 19 (19.8%) 0.487
(4.7%) 3 (3.1%) 0.623
(25.1%) 19 (19.8%) 0.278
 10.5 63.1 10.8 0.276
 41.0 142.9 47.4 0.048
 32.3 55.4 37.0 0.083
(9.9%) 12 (12.5%) 0.402
hout follow-up. †Effective dose (mSv) dose length product 0.014.
in Table 1.
76)nts (N  2,076)
I
MACE
(Cardiac Death, Nonfatal MI)
Annual
Event Rate
All Death,
Nonfatal MI
Annual
Event Rate
1 (0.2%) 0.13% 2 (0.3%) 0.26%
7 (0.8%) 0.52% 12 (1.4%) 0.87%
19 (3.6%) 3.25% 28 (5.4%) 4.61%
4 (4.1%) 5.79% 5 (5.2%) 8.31%
0.001 0.001
1 (0.2%) 0.13% 2 (0.3%) 0.26%
7 (0.8%) 0.52% 12 (1.4%) 0.87%
5 (1.6%) 1.44% 11 (3.4%) 2.76%
9 (5.3%) 4.30% 12 (7.1%) 6.41%
9 (7.0%) 9.79% 10 (7.8%) 10.52%
0.001 0.001
CAD (50%), high-risk CAD (left main stenosis [50%], or 3-vessel disease [70%] or 2-vessel
: patients were categorized into normal coronaries, nonobstructive CAD (50%), 1-, 2-, or 3-vesselts
llow-U
(n 
57.1
6.2
19.1
40.0
60.6
20.0
29.8
49.9
40.3
99.7
14.9
591
866
619
427
97
522
64.2
134.4
50.1
2052,0Eve
fatal M
(0%)
(0.6%)
(2.9%)
(3.1%)
.001
(0%)
(0.6%)
(1.3%)
(3.5%)
(6.3%)
.001
tructive
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Prognosis of Cardiac CT March 9, 2010:1017–28linical predictors was evaluated using the secondary out-
ome measure (all-cause mortality and nonfatal MI), which
ad 47 events. All 3 variables were independent predictors
f all-cause mortality and nonfatal MI. A statistically
ignificant increase in global chi-square values confirmed
nivariate Analysis of Clinical Characteristics for MACETable 4 Univariate Analysis of Clinical Characteristics for MAC
MACE
(n  31)
No MACE
(n  2,045)
Hazard Rat
(95% CI)
Age (yrs) 62.8 11.2 57.9 11.7 1.04 (1.01–1.
Male 21 (67.7%) 1,066 (52.1%) 1.97 (0.93–4.
Body mass index (kg/m2) 29.1 5.6 29.1 6.3 1.00 (0.94–1.
Pre-test likelihood for CAD (%)
Low 3 (9.7%) 680 (33.3%) 3.75 (2.13–6.
Intermediate 15 (48.4%) 1,091 (53.4%)
High 13 (41.9%) 274 (13.4%)
Cardiac risk factors
Diabetes 5 (16.1%) 295 (14.4%) 1.18 (0.45–3.
Dyslipidemia 20 (64.5%) 1,083 (53.0%) 1.59 (0.78–3.
Hypertension 19 (61.3%) 1,057 (51.7%) 1.49 (0.73–3.
Family history of CAD 13 (41.9%) 856 (41.9%) 0.87 (0.45–1.
Smoker/ex-smoker 25 (80.7%) 1,104 (54.0%) 3.58 (1.47–8.
NCEP/ATPIII risk
Low 1 (3.2%) 159 (7.8%) 3.32 (1.70–6.
Intermediate 12 (38.7%) 1,323 (64.7%)
High 18 (58.1%) 563 (27.5%)
Total plaque burden 8.74 3.89 3.89 3.98 1.33 (1.23–1.
LVEF (%)* 57.5 16.0 64.3 10.4 1.57 (1.24–1.
Left ventricular volumes could not be accurately measured in 53 patients (due to severe misregist
atients was used for analysis.
CI  confidence interval; LVEF  left ventricular ejection fraction; NCEP/ATPIII  National Chol
Cox Models of CTA Measures (CAD Model 1) anTable 5 Cox Models of CTA Measures (CAD
Models
Hazard Ratio
(95% CI)
Clinical variables
NCEP/ATPIII risk 2.01 (0.97–4.17
Pre-test likelihood for CAD 2.86 (1.55–5.25
Clinical  CAD
NCEP/ATPIII risk 1.78 (0.86–3.66
Pre-test likelihood for CAD 2.10 (1.16–3.79
CAD severity 3.02 (1.89–4.83
No CAD 0.25 (0.03–2.03
Nonobstructive CAD (50%) 1.0
Obstructive (50%), not high risk 4.14 (1.70–10.0
Obstructive, high risk 7.08 (2.02–24.7
Clinical  CAD  LVEF
NCEP/ATPIII risk 1.67 (0.80–3.45
Pre-test likelihood for CAD 2.10 (1.18–3.74
CAD severity 3.17 (1.97–5.09
No CAD 0.25 (0.03–2.07
Nonobstructive CAD (50%) 1.0
Obstructive (50%), not high risk 4.18 (1.72–10.1
Obstructive, high risk 8.10 (2.33–28.1
LVEF (10% reduction) 1.47 (1.17–1.86Abbreviations as in Tables 1 and 4.hat CAD severity (model 1) had incremental value over
linical predictors (58.61 vs. 31.38, p  0.001), LVEF has
ncremental value over CAD severity  clinical (78.88 vs.
8.61, p  0.001), and TPS had incremental value over
VEF  CAD  clinical (87.27 vs. 78.88, p  0.004)
Nonfatal MI
p Value
All-Cause
Mortality
(n  47)
No All-Cause
Mortality
(n  2,029)
Hazard Ratio
(95% CI) p Value
0.015 65.5 11.2 57.8 11.7 1.06 (1.04–1.09) 0.001
0.079 27 (57.5%) 1,060 (52.2%) 1.27 (0.71–2.27) 0.414
0.898 28.1 5.6 29.2 6.3 0.97 (0.92–1.02) 0.247
0.001 8 (17.0%) 675 (33.3%) 2.71 (1.73–4.23) 0.001
22 (46.8%) 1,084 (53.4%)
17 (36.2%) 270 (13.3%)
0.736 10 (21.3%) 290 (14.3%) 1.66 (0.83–3.35) 0.153
0.207 24 (51.1%) 1,079 (53.2%) 0.93 (0.53–1.64) 0.811
0.277 29 (61.7%) 1,047 (51.6%) 1.53 (0.85–2.73) 0.154
0.689 19 (40.4%) 850 (41.9%) 0.83 (0.48–1.44) 0.508
0.005 36 (76.6%) 1,093 (53.9%) 2.84 (1.44–5.58) 0.003
0.001 1 (2.1%) 159 (7.8%) 3.96 (2.27–6.90) 0.001
17 (36.2%) 1,318 (65.0%)
29 (61.7%) 552 (27.2%)
0.001 7.94 3.91 3.87 3.98 1.28 (1.20–1.37) 0.001
0.001 56.8 17.9 64.3 10.2 1.61 (1.34–1.94) 0.001
rtifact or poor signal-to-noise ratio at end systole); therefore, LVEF in the remaining 2,023 (97.4%)
Education Program/Adult Treatment Panel III; other abbreviations as in Tables 1 and 3.
CEel 1) and MACE
p Value
Global
Chi-Square Value
Model Comparisons
p Value
0.062 24.97
0.001
0.119 43.81 0.001
0.014
0.001
0.194
—
0.002
0.002
0.170 54.48 0.001
0.012
0.001
0.201
—
0.002
0.001
0.001E
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March 9, 2010:1017–28 Prognosis of Cardiac CTTable 6). When CAD severity was added to the model for
ll-cause mortality and nonfatal MI, the NRI was 15.9%
p  0.010), and further improved to 27.1% (p  0.001)
ith the addition of LVEF and TPS. When CAD severity
as added to the model for all-cause mortality, the NRI was
9.6% (p  0.010) (Table 7, Fig. 3).
laque characteristics. Using a scoring system similar to
PS, segments with visible noncalcific and calcific plaque were
ummed. Summed isolated noncalcific plaque scores did not
eem to have incremental value over CAD severity and LVEF;
owever, summed segments with isolated calcific plaque and
ummed segments with calcific plaque or mixed plaque seemed
o have similar incremental value as TPS (Table 8).
iscussion
ur study demonstrates that severity of CAD as measured
y 64-slice CTA has prognostic value and extends the
ndings of previously performed studies. We confirm that
he absence of obstructive CAD confers an excellent prog-
osis with an annual event rate 0.4% and that CAD
everity (HR: 3.02; 95% CI: 1.89 to 4.83) and every 10%
eduction in LVEF (HR: 1.47; 95% CI: 1.17 to 1.86) were
ndependent predictors of MACE. We also demonstrate
hat TPS was an independent predictor (HR: 1.17; 95% CI:
.06 to 1.29) and had incremental value for all-cause
ortality and nonfatal MI.
An understanding of a new modality’s diagnostic and
rognostic value is required before adopting it into clinical
ractice. Numerous studies demonstrated that CTA has
ery good operating characteristics, but data supporting its
Figure 1 Receiver-Operator Characteristic Curves of CAD Sever
Receiver-operator characteristic curves showing the incremental value of the coron
the curve [AUC]: 0.81; 95% confidence interval [CI]: 0.74 to 0.87) over clinical prerognostic value are limited. The results of our study iupport previous studies that demonstrated the prognostic
alue of CTA (6,7,28). However, our study expands on
revious literature by further investigating the prognosis of
4-slice CTA, in a large patient population using “hard”
ajor adverse events (cardiac death, nonfatal MI, and
ll-cause mortality) using LVEF and plaque burden.
rognostic value of CTA. Several groups examined the
rognostic value of CTA and showed that normal CTA
ndings confer an excellent prognosis and abnormal CTA
ndings are associated with adverse events (6–10). Using a
.S. national death registry, Min et al. (6) examined the
rognostic value of 16-slice CTA and Ostrom et al. (7)
tudied the prognostic value of electron beam CTA. In both
tudies, CAD severity and coronary atherosclerosis pre-
icted all-cause mortality. However, their studies were not
ble to stratify according to cause of death nor did they track
ther MACE such as cardiac death and nonfatal MI.
everal other CTA prognosis studies collected MACE as
nd points but have been small (8–10,28) with short
ollow-up (8,9), and some have been driven by early revas-
ularization (9,10). Our results expand on previous literature
y using 64-slice CTA, capturing MACE, but also high-
ighting the incremental value of LVEF and plaque burden.
rognostic value of LVEF. The prognostic value of
VEF has been well established and is used routinely in
linical practice. Because many centers perform CTA with a
etrospective ECG-gated acquisition protocol, LV volumes
re routinely available. Because LVEF measured by CTA
eems to be accurate and similar to measurements using
agnetic resonance imaging (29,30), it may be used as an
odel 1) and Clinical Predictors
ery disease (CAD) severity. Model 1 (solid line) (area under
(dashed line) (AUC: 0.72; 95% CI: 0.63 to 0.82, p  0.010).ity (M
ary art
dictorsndependent predictor of patient outcomes. The results of
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Prognosis of Cardiac CT March 9, 2010:1017–28ur study support the findings of previous studies and the
ncremental value of LVEF for MACE (12). We propose
hat LVEF be measured and reported whenever possible.
rognostic value of CT plaque imaging. CTA is a
oninvasive modality capable of detecting obstructive and
onobstructive CAD (2,3) and compares well with intra-
Cox Models of CTA Measures (CAD Model 1)and All-Cause Mortality and Nonfatal MITable 6 Cox Models of CTA Measures (CADand All-Cause Mortality and Nonfata
Models
Hazard Ratio
(95% CI)
Clinical variables
NCEP/ATPIII risk 2.98 (1.64–5.43
Pre-test likelihood for CAD 1.85 (1.17–2.94
Clinical  CAD
NCEP/ATPIII risk 2.56 (1.41–4.64
Pre-test likelihood for CAD 1.44 (0.92–2.25
CAD severity 2.82 (1.95–4.09
No CAD 0.27 (0.06–1.22
Nonobstructive CAD (50%) 1.0
Obstructive (50%), not high risk 3.79 (1.89–7.57
Obstructive, high risk 5.61 (1.94–16.2
Clinical  CAD  LVEF
NCEP/ATPIII risk 2.41 (1.32–4.39
Pre-test likelihood for CAD 1.44 (0.93–2.23
CAD severity 2.91 (2.00–4.24
No CAD 0.28 (0.06–1.26
Nonobstructive CAD (50%) 1.0
Obstructive (50%), not high risk 3.93 (1.96–7.88
Obstructive, high risk 6.15 (2.13–17.7
LVEF (10% reduction) 1.50 (1.25–1.81
Clinical  CAD  LVEF  TPS
NCEP/ATPIII risk 2.30 (1.26–4.21
Pre-test likelihood for CAD 1.31 (0.85–2.03
CAD severity 1.66 (0.98–2.80
No CAD 0.53 (0.11–2.54
Nonobstructive CAD (50%) 1.0
Obstructive (50%), not high risk 2.24 (1.02–4.92
Obstructive, high risk 2.21 (0.64–7.67
LVEF (10% reduction) 1.51 (1.26–1.82
TPS 1.17 (1.06–1.29
TPS  total plaque score; other abbreviations as in Tables 1 to 4.
Cox Models of CTA Measures (CAD Model 1) anTable 7 Cox Models of CTA Measures (CAD
Models
Hazard Ratio
(95% CI)
Clinical variables
NCEP/ATP III risk 3.85 (1.78–8.33
Pre-test likelihood for CAD 1.06 (0.60–1.90
Clinical  CAD
NCEP/ATP III risk 3.23 (1.49–7.01
Pre-test likelihood for CAD 0.88 (0.50–1.54
CAD severity 2.50 (1.55–4.04
No CAD 0.25 (0.03–2.03
Nonobstructive CAD (50%) 1.0
Obstructive (50%), not high risk 4.14 (1.70–10.0
Obstructive, high risk 7.08 (2.02–24.7Abbreviations as in Tables 1 and 4.ascular ultrasonography for the detection and/or exclusion
f atherosclerotic plaque (20,31–33). The identification of
ubclinical calcific and noncalcific atherosclerosis may be
mportant because 1) the extent of plaque has been shown to
redict myocardial ischemia (34); and 2) nonobstructive
esions are frequently the culprits in acute coronary syn-
el 1)
p Value
Global
Chi-Square Value
Model Comparisons
p Value
0.001 31.38
0.009
0.002 58.61 0.001
0.111
0.001
0.090
—
0.001
0.001
0.004 78.88 0.001
0.102
0.001
0.097
—
0.001
0.001
0.001
0.007 87.27 0.004
0.200
0.058
0.424
—
0.046
0.212
0.001
0.002
-Cause Mortalityel 1) and All-Cause Mortality
p Value
Global
Chi-Square Value
Model Comparisons
p Value
0.001 13.58
0.835
0.003 27.92 0.001
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0.001
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March 9, 2010:1017–28 Prognosis of Cardiac CTromes and sudden cardiac death (35,36). Matsumoto et al.
37) showed that patients with mild and moderate coronary
tenoses (25% to 75% stenosis) had annual death and acute
oronary syndrome event rates of 0.25% and 0.93%, respec-
ively. Motoyama et al. (38) demonstrated that coronary
egments with positive remodeling and low attenuation
laques were predictors of acute coronary syndromes. Al-
hough investigators are beginning to focus on specific
laque characteristics that hold promise, we sought a simple
easure that can be easily performed and incorporated into
linical practice. Interobserver variability was assessed in a
ubgroup of 828 patients and demonstrated very good
orrelation between readers (r  0.92, p  0.001). The
esults of our study demonstrate that a simple measure of
laque (TPS) was a predictor of all-cause mortality and
onfatal MI and had incremental value over CAD and
VEF. Due to potential model overfitting error, the incre-
ental value of TPS could not be assessed using our primary
utcome of MACE but should be a focus of future studies.
Acknowledging the potential value of plaque composi-
ion, we also examined plaque characteristics. Although
solated noncalcific plaque did not seem to have incremental
alue over CAD severity and LVEF, summed segments
Incremental Values of Plaque CharacteristicsOver CTA Meas res (CAD Model 1) for MACETable 8 Incremental Values of Plaque haraOver CTA Measures (CAD Model 1)
Models
Hazard R
(95%
CAD  LVEF
CAD severity 3.67 (2.36
LVEF (10% reduction) 1.49 (1.18
CAD  LVEF  isolated noncalcific plaque
CAD severity 3.48 (2.20
LVEF (10% reduction) 1.52 (1.20
Only soft plaque score 1.11 (0.93
CAD  LVEF  isolated calcific plaque
CAD severity 3.32 (2.09
LVEF (10% reduction) 1.50 (1.19
Isolated calcific plaque 1.15 (1.01
CAD  LVEF  noncalcific and mixed plaque
CAD severity 2.34 (1.30
LVEF (10% reduction) 1.52 (1.20
Noncalcific and mixed plaque 1.15 (1.02
CAD  LVEF  mixed plaque
CAD severity 2.64 (1.51
LVEF (10% reduction) 1.49 (1.18
Mixed plaque 1.13 (1.00
CAD  LVEF  calcific and mixed plaque
CAD severity 2.10 (1.18
LVEF (10% reduction) 1.48 (1.18
Calcific and mixed plaque 1.18 (1.06
CAD  LVEF  TPS
CAD severity 1.55 (0.83
LVEF (10% reduction) 1.53 (1.21
TPS 1.27 (1.13
*Compared with the model CAD  LVEF.
Abbreviations as in Tables 1 to 4 and 6.ith calcific and/or mixed plaque and TPS seemed to have Ahe greatest incremental value. Plaque with calcific compo-
ents may be an important feature in predicting adverse
vents; however, further research is needed.
onfatal MI. Recognizing that MI post-percutaneous in-
ervention (type IV MI) could increase event rates, all MI
ecords were reviewed. One patient had a type IV MI, but
xcluding this patient from analysis did not change study
esults.
ll-cause mortality. We observed a lower rate of all-cause
ortality in patients with high-risk CAD than non–high-
isk CAD. Although these results were unexpected, 2
easons may be offered. 1) It is possible that, due to the small
opulation of patients with high-risk CAD, these observa-
ions occurred by chance. 2) One may also speculate that
here may have been fewer noncardiac deaths in revascular-
zed patients because they may have been better able to
olerate noncardiac illnesses such as sepsis.
tudy limitations. This was a single-center, prospective
tudy, and the results of our study may not necessarily reflect
he patient population or physician practice at other centers.
iven the limited number of events, we recognize that our
nalysis is subject to overfitting; however, a recent article
39) suggests that current rules may be too conservative.
stics
ACE
p Value
Global
Chi-Square Value
Model Comparisons
p Value*
0.001 48.50
0.001
0.001 48.65 0.699
0.001
0.262
0.001 52.77 0.039
0.001
0.036
0.005 53.56 0.024
0.001
0.018
0.001 53.89 0.020
0.001
0.053
0.012 57.45 0.003
0.001
0.002
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0.001
0.001cteri
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Prognosis of Cardiac CT March 9, 2010:1017–28nlikely. Our results are similar to those of previous prog-
ostic studies and thus lend further evidence to the prog-
ostic value of CTA. Large multicenter cohort studies with
xtended follow-up are still required to fully comprehend
he prognostic value of CTA.
We also recognize that incomplete follow-up may result
n underreporting of MACE. However, the follow-up in
ur study was excellent (95.6%) and similar to that of
revious prognostic studies (40). Because the 96 patients
ost to follow-up were younger (Table 1), we do not believe
hat there is significant bias introduced by the lost to
ollow-up group. In addition, because cardiac catheteriza-
ion services and cardiac surgery are centralized to our
ertiary-care center (servicing a population of 1.5 million to
.8 million), the majority of cardiac events and revascular-
zation procedures would have been performed locally and
Figure 2 Risk-Adjusted MACE-Free Survival as a Function of CA
(A) Risk-adjusted major adverse coronary event (MACE)-free survival as a function
erosclerosis (blue line), nonobstructive CAD (green line), non–high-risk CAD (red
survival as a function of CAD severity (model 2) for patients without coronary athe
line), double-vessel disease (black line), and triple-vessel disease (purple line); lohus captured in our database. oIt is accepted that coronary calcium scores have prognos-
ic value in the asymptomatic population (13). Because our
opulation was primarily symptomatic, coronary calcium
cores were not routinely performed. Although the incre-
ental value of the Agatston score over CTA and LVEF
ould not be assessed, summed segments with isolated
alcific plaque did not seem to have incremental value over
PS, but summed segments with calcific and/or mixed
laque had similar value as TPS.
We recognize that contrast administration and image
cquisition protocols vary among physicians and centers. In
ur study, contrast flow rates were left to the discretion of
he physician, which may lead to protocol inconsistencies;
owever, we believe that these effects are minimal because
he local practice of physicians is similar.
uture directions. The results of our study and those of
verity: Models 1 and 2
onary artery disease (CAD) severity (model 1) for patients without coronary ath-
nd high-risk CAD (black line); log rank p  0.001. (B) Risk-adjusted MACE-free
osis (blue line), nonobstructive CAD (green line), single-vessel disease (red
p  0.001.D Se
of cor
line), a
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g rankthers have demonstrated the potential prognostic value of
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March 9, 2010:1017–28 Prognosis of Cardiac CTTA; however, further studies are needed. Other measures
f CAD severity, such as the Duke CAD index, may prove
o have value in CTA, but require further investigation (23).
The functional assessment of CAD has incremental
rognostic value (41). Whether functional assessment with
TA (42) or other noninvasive modalities has incremental
alue over the severity of CAD, TPS, and LVEF requires
urther investigation. In addition, of great interest would be
he direct comparison of the prognostic value of CTA with
ther accepted noninvasive modalities.
Although earlier identification of nonobstructive CAD
eems desirable, enthusiasm must be tempered by the fact
hat the treatment of nonobstructive CAD has not been
hown to reduce cardiac morbidity and mortality in a
ost-effective manner. Studies examining the beneficial
mpact of early coronary atherosclerosis detection, plaque
haracterization, and therapy are also required.
onclusions
ssessment of CAD severity, TPS, and LVEF with CTA
as prognostic value and has incremental value over routine
linical predictors. Although CAD severity is the strongest
redictor of adverse events, LVEF and TPS seem to have
ncremental value. Plaque with calcific components seems to
e associated with MACE, but further studies are required.
TA seems to be a promising noninvasive modality with
rognostic value.
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